BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 24903273)

  • 1. Heat-shock protein 27 (HSP27, HSPB1) is up-regulated by MET kinase inhibitors and confers resistance to MET-targeted therapy.
    Musiani D; Konda JD; Pavan S; Torchiaro E; Sassi F; Noghero A; Erriquez J; Perera T; Olivero M; Di Renzo MF
    FASEB J; 2014 Sep; 28(9):4055-67. PubMed ID: 24903273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heat-shock protein 27 (HSP27, HSPB1) is synthetic lethal to cells with oncogenic activation of MET, EGFR and BRAF.
    Konda JD; Olivero M; Musiani D; Lamba S; Di Renzo MF
    Mol Oncol; 2017 Jun; 11(6):599-611. PubMed ID: 28182330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells.
    Bachleitner-Hofmann T; Sun MY; Chen CT; Tang L; Song L; Zeng Z; Shah M; Christensen JG; Rosen N; Solit DB; Weiser MR
    Mol Cancer Ther; 2008 Nov; 7(11):3499-508. PubMed ID: 18974395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells.
    Chen CT; Kim H; Liska D; Gao S; Christensen JG; Weiser MR
    Mol Cancer Ther; 2012 Mar; 11(3):660-9. PubMed ID: 22238368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitogen-activated protein kinase-activated protein kinase 2 mediates resistance to hydrogen peroxide-induced oxidative stress in human hepatobiliary cancer cells.
    Nguyen Ho-Bouldoires TH; Clapéron A; Mergey M; Wendum D; Desbois-Mouthon C; Tahraoui S; Fartoux L; Chettouh H; Merabtene F; Scatton O; Gaestel M; Praz F; Housset C; Fouassier L
    Free Radic Biol Med; 2015 Dec; 89():34-46. PubMed ID: 26169728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heat shock protein 27 regulates human prostate cancer cell motility and metastatic progression.
    Voll EA; Ogden IM; Pavese JM; Huang X; Xu L; Jovanovic BD; Bergan RC
    Oncotarget; 2014 May; 5(9):2648-63. PubMed ID: 24798191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of short-form RON as a novel intrinsic resistance mechanism for anti-MET therapy in MET-positive gastric cancer.
    Wu Z; Zhang Z; Ge X; Lin Y; Dai C; Chang J; Liu X; Geng R; Wang C; Chen H; Sun M; Guo W; Li J
    Oncotarget; 2015 Dec; 6(38):40519-34. PubMed ID: 26528757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy.
    Brevet M; Shimizu S; Bott MJ; Shukla N; Zhou Q; Olshen AB; Rusch V; Ladanyi M
    J Thorac Oncol; 2011 May; 6(5):864-74. PubMed ID: 21774103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer.
    Lamoureux F; Thomas C; Yin MJ; Fazli L; Zoubeidi A; Gleave ME
    Eur Urol; 2014 Jul; 66(1):145-55. PubMed ID: 24411988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SAHA triggered MET activation contributes to SAHA tolerance in solid cancer cells.
    Ding L; Zhang Z; Liang G; Yao Z; Wu H; Wang B; Zhang J; Tariq M; Ying M; Yang B
    Cancer Lett; 2015 Jan; 356(2 Pt B):828-36. PubMed ID: 25449774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplified tumor cells with or without resistance to selective MET Inhibition.
    Bachleitner-Hofmann T; Sun MY; Chen CT; Liska D; Zeng Z; Viale A; Olshen AB; Mittlboeck M; Christensen JG; Rosen N; Solit DB; Weiser MR
    Clin Cancer Res; 2011 Jan; 17(1):122-33. PubMed ID: 21208906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HSP27 is required for invasion and metastasis triggered by hepatocyte growth factor.
    Pavan S; Musiani D; Torchiaro E; Migliardi G; Gai M; Di Cunto F; Erriquez J; Olivero M; Di Renzo MF
    Int J Cancer; 2014 Mar; 134(6):1289-99. PubMed ID: 23996744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors.
    Qi J; McTigue MA; Rogers A; Lifshits E; Christensen JG; Jänne PA; Engelman JA
    Cancer Res; 2011 Feb; 71(3):1081-91. PubMed ID: 21266357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition.
    Corso S; Ghiso E; Cepero V; Sierra JR; Migliore C; Bertotti A; Trusolino L; Comoglio PM; Giordano S
    Mol Cancer; 2010 May; 9():121. PubMed ID: 20500904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small interfering RNA-mediated silencing of heat shock protein 27 (HSP27) Increases chemosensitivity to paclitaxel by increasing production of reactive oxygen species in human ovarian cancer cells (HO8910).
    Song TF; Zhang ZF; Liu L; Yang T; Jiang J; Li P
    J Int Med Res; 2009; 37(5):1375-88. PubMed ID: 19930842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of PI3K p110α contributes to acquired resistance to MET inhibitor, in MET-amplified SNU-5 gastric xenografts.
    Ji F; Liu X; Wu Y; Fang X; Huang G
    Drug Des Devel Ther; 2015; 9():5697-704. PubMed ID: 26543351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hsp27 Inhibition with OGX-427 Sensitizes Non-Small Cell Lung Cancer Cells to Erlotinib and Chemotherapy.
    Lelj-Garolla B; Kumano M; Beraldi E; Nappi L; Rocchi P; Ionescu DN; Fazli L; Zoubeidi A; Gleave ME
    Mol Cancer Ther; 2015 May; 14(5):1107-16. PubMed ID: 25740245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
    Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
    Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel lead compound CM-118: antitumor activity and new insight into the molecular mechanism and combination therapy strategy in c-Met- and ALK-dependent cancers.
    Meng L; Shu M; Chen Y; Yang D; He Q; Zhao H; Feng Z; Liang C; Yu K
    Cancer Biol Ther; 2014 Jun; 15(6):721-34. PubMed ID: 24618813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of Src impairs the growth of met-addicted gastric tumors.
    Bertotti A; Bracco C; Girolami F; Torti D; Gastaldi S; Galimi F; Medico E; Elvin P; Comoglio PM; Trusolino L
    Clin Cancer Res; 2010 Aug; 16(15):3933-43. PubMed ID: 20628031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.